UHG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
UHG is not a good buy right now for an impatient investor. The stock just sold off hard in the regular session (-7.48%) and there are no Intellectia buy signals, no fresh news catalysts, and the latest quarter shows declining revenue and weakening gross margin despite a reduced loss. With the setup still mixed/fragile, the better call is to hold/avoid initiating a new position at this moment.
Price action is weak near-term: the stock fell -7.48% in the regular session and is only slightly higher post-market (~2.01). Momentum is not decisively bullish: MACD histogram is above zero (0.032) but positively contracting (bullish momentum is fading), RSI(6) ~54 is neutral, and moving averages are converging (often a consolidation/indecision phase rather than a clear uptrend). Key levels: pivot support ~1.912 (price is slightly above, which is constructive), with resistance at ~2.187 then ~2.357. A clean break above 2.187 would improve the technical picture; losing 1.912 increases risk of a move toward ~1.637. Intellectia signals: AI Stock Picker = no signal today; SwingMax = no recent signal, so there is no strong systematic ‘buy now’ trigger.
Price is holding slightly above the pivot support (~1.912), which can allow for a short rebound if buyers defend that level. Pattern-based projection suggests modest upside odds over the next week/month (+2.02% next week, +1.15% next month), though near-term (next day) skews slightly negative.
Sharp regular-session drop (-7.48%) indicates recent selling pressure. No recent news to re-rate the stock or provide an event-driven tailwind. No hedge fund/insider accumulation trend reported recently. Technical momentum is mixed with MACD contracting and no proprietary buy signals from Intellectia modules. If price breaks below ~1.912, downside risk increases toward ~1.637.
2025/Q3 results show weakening top-line and profitability quality: revenue fell to 90.79M (-23.47% YoY) and gross margin declined to 17.68% (-6.31% YoY). Net income improved YoY (loss narrowed to -31.30M, +326.41% YoY) and EPS improved to -0.53 (+253.33% YoY), but the company is still loss-making and margins are compressing—overall not a strong growth setup.
No analyst rating or price-target change data was provided, so a Wall Street pros/cons consensus view cannot be confirmed from the dataset.
